Description: SB 242235 is a potent and selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases. Target: p38 MAPK, Autophagy. Smiles: COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1. References: Badger, A.M., et al., Differential effects of SB 242235, a selective p38...

Soluble in DMSO. The p38 mitogen-activated protein kinase (MAPK) signaling pathway is activated by numerous inflammatory mediators and environmental stresses. SB-242235 is a potent and moderately selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases such as autoimmune or...

SB-242235 is an inhibitor of p38alpha MAPK (IC50 = 0.019 µM). It is selective for p38alpha MAPK over a panel of 10 kinases, including ERK2, JNK1, EGFR, and C-RAF (IC50s = >10 µM for all). SB-242235 inhibits IL-1alpha-induced production of nitric oxide (NO) in bovine articular cartilage explants but not...